海外の治験の状況「1」での検索結果
199件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Recruiting
- A PHASE III, RANDOMIZED, MULTI-CENTER, OPEN-LABEL, COMPARATIVE GLOBAL STUDY TO DETERMINE THE EFFICACY OF DURVALUMAB OR DURVALUMAB AND TREMELIMUMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY FOR FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) (POSEIDON)
- -C34 Malignant neoplasm of bronchus and lung Malignant neoplasm of bronchus and lung;Malignant neoplasm of bronchus and lung
- Brazil, Bulgaria, Germany, Japan, Korea South, Mexico, Peru, Russian Federation, South Africa, Taiwan, Thailand, Ukraine, United Kindgdom, United States
- 2017-09-14
Recruiting
- A Randomized, Double-blind, Multi-center Phase III Study of Brivanib versus Sorafenib as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma
- Advanced Hepatocellular Carcinoma C22.0 C04.588.274.623;C00-D48;C04.588.274.623
- Australia, Belgium, Brazil, Canada, China, Czech Republic, France, Germany, Hong Kong, India, Italy, Japan, Korea, Democratic People's Republic of, Poland, Russian Federation, South Africa, Sweden, Taiwan, Province of China, Thailand, Turkey, United Kingdom, United States
- 2011-06-27
Recruiting
- A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer with Non-Squamous Histology
- Recurrent or Advanced Non-Small Cell Lung Cancer with Non-Squamous Histology C04.588.894.797.520.109.220.249;C00-D48;C04.588.894.797.520.109.220.249
- Brazil, France, Italy, Poland, Russian Federation, South Africa, United Kingdom
- 2011-06-13
Recruiting
- A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 in Combination With Tremelimumab Versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer (SCCHN) Patients
- Squamous Cell Carcinoma of the Head and Neck
- Belgium, Brazil, Canada, France, Greece, India, Italy, Japan, Korea, Republic of, Philippines, Poland, Romania, Slovakia, Spain, Taiwan, Province of China, Thailand, Ukraine, United Kingdom, United States, Viet Nam
- 2016-03-22
Recruiting
- Eltrombopag Combined With Cyclosporine (antibiotic) as First Line Therapy in Patients With Severe Acquired Aplastic Anemia
- Patients with severe acquired aplastic anemia
- Brazil, Canada, France, Hong Kong, Hungary, India, Italy, Mexico, Qatar, Republic of Korea, Spain, Turkey
- 2017-06-22
Recruiting
- Mesenchymal Stem Cells as First Treatment Line for Resistant Acute Graft Versus Host Disease
- Graft vs Host Disease
- Brazil
- 2015-10-08
Recruiting
- Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/ENGOT-ov43/KEYLYNK-001)
- Ovarian Cancer;Fallopian Tube Cancer;Peritoneal Neoplasms
- Belgium, Canada, Chile, Israel, Japan, Korea, Republic of, Poland, Russian Federation, Spain, Taiwan
- 2018-11-12
Recruiting
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
- Carcinoma, Hepatocellular
- Australia, Chile, China, France, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Spain, Taiwan, Turkey, United Kingdom, United States
- 2018-10-18
Recruiting
- Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
- Metastatic Castration-resistant Prostate Cancer
- Australia, Belgium, Brazil, Canada, Chile, China, Czechia, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Slovakia, Spain, Turkey, United Kingdom, United States
- 2018-09-28
Recruiting
- Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)
- Cervical Cancer
- Argentina, Australia, Canada, Chile, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Russian Federation, Spain, Taiwan, Turkey, Ukraine, United States
- 2018-08-15
